| Literature DB >> 30133305 |
Muath Helal1, Ekaterina Dadachova1.
Abstract
In the past several decades, many antimicrobial agents have been used in treating different fungal, bacterial, and viral infections. However, these agents have faced challenges such as pronounced side-effect profiles and pathogen resistance. In addition, a cure for many chronic infections such as human immunodeficiency virus (HIV) has not been achieved, and the incidence of opportunistic infections in immunocompromised patients has increased significantly in the past decades. Therefore, an alternative strategy for combating these infections is needed. Radioimmunotherapy (RIT) has been proposed to be a valuable tool in the management of such infections. The side-effects associated with RIT are minimal as the targeted antigens are only expressed on microbial or infected cells. RIT demonstrated impressive potency in eradicating pathogens in animal models and patient samples. Cryptococcus neoformans, HIV, and Bacillus anthracis are few examples of infections for which RIT has been an effective treatment using radionuclides such as bismuth-213 (213Bi) or rhenium-188 (188Re).Entities:
Keywords: HIV; bacterial infections; fungal infections; monoclonal antibody; radioimmunotherapy
Mesh:
Substances:
Year: 2018 PMID: 30133305 PMCID: PMC6207155 DOI: 10.1089/cbr.2018.2481
Source DB: PubMed Journal: Cancer Biother Radiopharm ISSN: 1084-9785 Impact factor: 3.099